Drug Profile
Research programme: FabH inhibitors - DeNovaMed
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator DeNovaMed
- Class
- Mechanism of Action FabH inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Bacterial-infections in United Kingdom
- 28 Feb 2018 No recent reports of development identified for research development in Gram-positive-infections in United Kingdom
- 28 Feb 2018 No recent reports of development identified for research development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom